                         SEQUENCE LISTING

<110>  Agency for Science, Technology and Research
 
<120>  Self-Assembling Ultrashort Aliphatic Cyclic Peptides for 
       Biomedical Applications

<130>  A32687WO

<150>  SG10201502526Y
<151>  2015-03-31

<160>  52    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  1

Leu Ile Val Ala Gly 
1               5   


<210>  2
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  2

Ile Leu Val Ala Gly 
1               5   


<210>  3
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  3

Leu Ile Val Ala Ala 
1               5   


<210>  4
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  4

Leu Ala Val Ala Gly 
1               5   


<210>  5
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  5

Ile Val Ala Gly 
1               


<210>  6
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  6

Leu Val Ala Gly 
1               


<210>  7
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  7

Ile Leu Val Ala 
1               


<210>  8
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  8

Leu Ile Val Ala 
1               


<210>  9
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  9

Leu Ile Val Gly 
1               


<210>  10
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  10

Ala Ile Val Ala Gly 
1               5   


<210>  11
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  11

Gly Ile Val Ala Gly 
1               5   


<210>  12
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  12

Val Ile Val Ala Gly 
1               5   


<210>  13
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  13

Ala Leu Val Ala Gly 
1               5   


<210>  14
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  14

Gly Leu Val Ala Gly 
1               5   


<210>  15
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a of cyclic peptide

<400>  15

Val Leu Val Ala Gly 
1               5   


<210>  16
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  16

Leu Ile Val Ala Gly Lys 
1               5       


<210>  17
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  17

Ile Leu Val Ala Gly Lys 
1               5       


<210>  18
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  18

Leu Ile Val Ala Ala Lys 
1               5       


<210>  19
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  19

Leu Ala Val Ala Gly Lys 
1               5       


<210>  20
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  20

Ala Ile Val Ala Gly Lys 
1               5       


<210>  21
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  21

Leu Ile Val Ala Gly Ser 
1               5       


<210>  22
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  22

Ile Leu Val Ala Gly Ser 
1               5       


<210>  23
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  23

Leu Ile Val Ala Ala Ser 
1               5       


<210>  24
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  24

Leu Ala Val Ala Gly Ser 
1               5       


<210>  25
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  25

Ala Ile Val Ala Gly Ser 
1               5       


<210>  26
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  26

Leu Ile Val Ala Gly Asp 
1               5       


<210>  27
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  27

Ile Leu Val Ala Gly Asp 
1               5       


<210>  28
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  28

Leu Ile Val Ala Ala Asp 
1               5       


<210>  29
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  29

Leu Ala Val Ala Gly Asp 
1               5       


<210>  30
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  30

Ala Ile Val Ala Gly Asp 
1               5       


<210>  31
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  31

Leu Ile Val Ala Gly Glu 
1               5       


<210>  32
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  32

Leu Ile Val Ala Gly Thr 
1               5       


<210>  33
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  33

Ile Leu Val Ala Gly Thr 
1               5       


<210>  34
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  34

Ala Ile Val Ala Gly Thr 
1               5       


<210>  35
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  35

Ala Ile Val Ala Gly Lys 
1               5       


<210>  36
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  36

Leu Ile Val Ala Asp 
1               5   


<210>  37
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  37

Leu Ile Val Gly Asp 
1               5   


<210>  38
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  38

Ile Val Ala Asp 
1               


<210>  39
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  39

Ile Val Ala Lys 
1               


<210>  40
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide wherein Xaa = ornithine (Orn)


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be any naturally occurring amino acid

<400>  40

Leu Ile Val Ala Gly Xaa 
1               5       


<210>  41
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide wherein Xaa = ornithine (Orn)


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be any naturally occurring amino acid

<400>  41

Ile Leu Val Ala Gly Xaa 
1               5       


<210>  42
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide wherein Xaa = ornithine (Orn)


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be any naturally occurring amino acid

<400>  42

Ala Ile Val Ala Gly Xaa 
1               5       


<210>  43
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide wherein Xaa = 2,4-diaminobutyric acid
       (Dab)


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be any naturally occurring amino acid

<400>  43

Leu Ile Val Ala Gly Xaa 
1               5       


<210>  44
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide wherein Xaa = 2,4-diaminobutyric acid
       (Dab)


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be any naturally occurring amino acid

<400>  44

Ile Leu Val Ala Gly Xaa 
1               5       


<210>  45
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide wherein Xaa = 2,4-diaminobutyric acid
       (Dab)


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be any naturally occurring amino acid

<400>  45

Ala Ile Val Ala Gly Xaa 
1               5       


<210>  46
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide wherein Xaa = 2,3-diaminopropionic 
       acid (Dap)


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be any naturally occurring amino acid

<400>  46

Leu Ile Val Ala Gly Xaa 
1               5       


<210>  47
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide wherein Xaa = 2,3-diaminopropionic 
       acid (Dap)


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be any naturally occurring amino acid

<400>  47

Ile Leu Val Ala Gly Xaa 
1               5       


<210>  48
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide wherein Xaa = 2,3-diaminopropionic 
       acid (Dap)


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa can be any naturally occurring amino acid

<400>  48

Ala Ile Val Ala Gly Xaa 
1               5       


<210>  49
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  49

Leu Ile Val Ala Gly Lys Lys 
1               5           


<210>  50
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  50

Leu Ile Val Ala Gly Ser Ser 
1               5           


<210>  51
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  51

Leu Ile Val Ala Gly Asp Asp 
1               5           


<210>  52
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (X)a-(Y)b of cyclic peptide

<400>  52

Leu Ile Val Ala Gly Glu Glu 
1               5           


